AGENT FOR ENHANCING THE PRODUCTION OF CYTOKINES AND/OR CHEMOKINES
    1.
    发明申请
    AGENT FOR ENHANCING THE PRODUCTION OF CYTOKINES AND/OR CHEMOKINES 审中-公开
    用于增强细胞因子和/或细胞因子生产的代理

    公开(公告)号:US20090148943A1

    公开(公告)日:2009-06-11

    申请号:US12265348

    申请日:2008-11-05

    IPC分类号: C12N5/06

    CPC分类号: C07K14/4705 A61K38/00

    摘要: The present invention has an object to provide a means to effectively enhance the production of cytokines and/or chemokines in mammals. The object is solved by providing an agent for enhancing the production of cytokines and/or chemokines, which comprises, as an effective ingredient, a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3; a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3, where one or more amino acids thereof are deleted or replaced with other amino acid(s) and/or one or more amino acids are added thereunto, without substantially losing the biological activity of the polypeptide.

    摘要翻译: 本发明的目的是提供有效增强哺乳动物中细胞因子和/或趋化因子的产生的方法。 通过提供用于增强细胞因子和/或趋化因子的产生的试剂来解决该问题,所述试剂包含作为有效成分的具有SEQ ID NO:1至3的任一氨基酸序列的多肽; 具有SEQ ID NO:1至3的任何一个氨基酸序列的多肽,其中一个或多个氨基酸被缺失或被其它氨基酸和/或一个或多个氨基酸所取代,而没有 基本上丧失了多肽的生物活性。

    Agent for enhancing the production of cytokines and/or chemokines
    2.
    发明申请
    Agent for enhancing the production of cytokines and/or chemokines 审中-公开
    用于增强细胞因子和/或趋化因子产生的药剂

    公开(公告)号:US20070110711A1

    公开(公告)日:2007-05-17

    申请号:US11583148

    申请日:2006-10-19

    IPC分类号: A61K38/19 C07K14/52

    CPC分类号: C07K14/4705 A61K38/00

    摘要: The present invention has an object to provide a means to effectively enhance the production of cytokines and/or chemokines in mammals. The object is solved by providing an agent for enhancing the production of cytokines and/or chemokines, which comprises, as an effective ingredient, a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3; a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3, where one or more amino acids thereof are deleted or replaced with other amino acid(s) and/or one or more amino acids are added thereunto, without substantially losing the biological activity of the polypeptide.

    摘要翻译: 本发明的目的是提供有效增强哺乳动物中细胞因子和/或趋化因子的产生的方法。 通过提供用于增强细胞因子和/或趋化因子的产生的试剂来解决该问题,所述试剂包含作为有效成分的具有SEQ ID NO:1至3的任一氨基酸序列的多肽; 具有SEQ ID NO:1至3的任何一个氨基酸序列的多肽,其中一个或多个氨基酸被缺失或被其它氨基酸和/或一个或多个氨基酸加入,而没有 基本上丧失了多肽的生物活性。

    Human tumor necrosis factor-α mutants
    3.
    发明授权
    Human tumor necrosis factor-α mutants 有权
    人肿瘤坏死因子-α突变体

    公开(公告)号:US08187584B2

    公开(公告)日:2012-05-29

    申请号:US13205053

    申请日:2011-08-08

    IPC分类号: A61K38/19 C07K14/525

    摘要: The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.

    摘要翻译: 本发明的目的是提供肿瘤坏死因子突变蛋白,特别是TNF-R1或TNF-R2特异的肿瘤坏死因子突变体蛋白; 肿瘤坏死因子抑制剂; 或含有其作为有效成分的肿瘤坏死因子制剂,其目的是通过提供一种或多种选自第29,31,32,35,146和147位的氨基酸残基的肿瘤坏死因子突变蛋白来解决, 或由SEQ ID NO:1的氨基酸序列的N末端第84位至第89位的基团被其它氨基酸残基取代; 肿瘤坏死因子抑制剂; 和含有它作为有效成分的肿瘤坏死因子制剂。

    Tumor necrosis factor-alpha mutants
    4.
    发明授权
    Tumor necrosis factor-alpha mutants 有权
    肿瘤坏死因子-α突变体

    公开(公告)号:US07993636B2

    公开(公告)日:2011-08-09

    申请号:US10585296

    申请日:2005-01-05

    IPC分类号: C07K14/525

    摘要: The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.

    摘要翻译: 本发明的目的是提供肿瘤坏死因子突变蛋白,特别是TNF-R1或TNF-R2特异的肿瘤坏死因子突变体蛋白; 肿瘤坏死因子抑制剂; 或含有其作为有效成分的肿瘤坏死因子制剂,其目的是通过提供一种或多种选自第29,31,32,35,146和147位的氨基酸残基的肿瘤坏死因子突变蛋白来解决, 或由SEQ ID NO:1的氨基酸序列的N末端第84位至第89位的基团被其它氨基酸残基取代; 肿瘤坏死因子抑制剂; 和含有它作为有效成分的肿瘤坏死因子制剂。

    MONOCLONAL ANTIBODY SPECIFIC TO BOTH HUMAN INTERFERON-ALPHA SUBTYPE ALPHA 8 AND ITS MUTANT PROTEINS
    6.
    发明申请
    MONOCLONAL ANTIBODY SPECIFIC TO BOTH HUMAN INTERFERON-ALPHA SUBTYPE ALPHA 8 AND ITS MUTANT PROTEINS 失效
    人类干扰素ALPHA亚型ALPHA 8及其突变蛋白特异性单克隆抗体

    公开(公告)号:US20110091968A1

    公开(公告)日:2011-04-21

    申请号:US12933768

    申请日:2009-03-16

    摘要: The present invention has the first object to provide a monoclonal antibody specific to interferon α subtype α8 (IFNα8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFNα8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFNα8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8. The present invention solves the above objects by providing a monoclonal antibody specific to IFNα8 and its mutant proteins, a hybridoma capable of producing the monoclonal antibody, a method for detecting the IFNα8 and its mutant proteins by immunoreaction using the monoclonal antibody, a method for purifying the IFNα8 and its mutant proteins using the monoclonal antibody, and a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8, which contains the monoclonal antibody as an effective ingredient.

    摘要翻译: 本发明的第一个目的是提供对干扰素α亚型α8(IFNα8)及其突变蛋白特异性的单克隆抗体,第二个目的是提供能产生单克隆抗体的杂交瘤,第三个目的是提供一种检测方法 通过单克隆抗体IFNα8及其突变蛋白,第四个目的是提供通过单克隆抗体纯化IFNα8及其突变蛋白的方法,第五个目的是提供一种用于治疗其发作或加重与IFNα8相关的疾病的治疗剂 。 本发明通过提供对IFNα8及其突变蛋白特异性的单克隆抗体,能够产生单克隆抗体的杂交瘤,通过使用单克隆抗体的免疫反应检测IFNα8及其突变蛋白的方法来解决上述目的,纯化方法 使用单克隆抗体的IFNα8及其突变蛋白,以及用于治疗其发作或恶化与IFNα8相关的疾病的治疗剂,其含有单克隆抗体作为有效成分。

    TUMOR NECROSIS FACTOR-ALPHA MUTANTS
    9.
    发明申请
    TUMOR NECROSIS FACTOR-ALPHA MUTANTS 有权
    肿瘤坏死因子-ALPHA突变体

    公开(公告)号:US20110293555A1

    公开(公告)日:2011-12-01

    申请号:US13205053

    申请日:2011-08-08

    摘要: The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.

    摘要翻译: 本发明的目的是提供肿瘤坏死因子突变蛋白,特别是TNF-R1或TNF-R2特异的肿瘤坏死因子突变体蛋白; 肿瘤坏死因子抑制剂; 或含有其作为有效成分的肿瘤坏死因子制剂,其目的是通过提供一种或多种选自第29,31,32,35,146和147位的氨基酸残基的肿瘤坏死因子突变蛋白来解决, 或由SEQ ID NO:1的氨基酸序列的N末端第84位至第89位的基团被其它氨基酸残基取代; 肿瘤坏死因子抑制剂; 和含有它作为有效成分的肿瘤坏死因子制剂。

    Recombinant DNA and transformant containing the same
    10.
    发明授权
    Recombinant DNA and transformant containing the same 失效
    重组DNA和含有其的转化体

    公开(公告)号:US5731193A

    公开(公告)日:1998-03-24

    申请号:US828511

    申请日:1997-03-31

    摘要: Insertion of IFN-alpha promoters in recombinant DNAs improves their expression efficiencies for useful polypeptides. Expression of such a recombinant DNA in host cells of mammalian origin is artificially controllable by the presence and absence of external stimuli using IFN-alpha inducers. Thus, transformants with such a recombinant DNA readily increase to a maximized cell density with causing neither damages nor extinction due to polypeptides they produce, and subsequent exposure to IFN-alpha inducers allows the proliferated cells to efficiently produce polypeptides with significant glycosylations.

    摘要翻译: 在重组DNA中插入IFN-α启动子改善了其对有用多肽的表达效率。 这种重组DNA在哺乳动物来源的宿主细胞中的表达可以通过使用IFN-α诱导物的外部刺激的存在和不存在来人为可控。 因此,具有这种重组DNA的转化体容易增加到最大化的细胞密度,由于它们产生的多肽而不造成损伤或消灭,随后暴露于IFN-α诱导物允许增殖的细胞有效地产生具有显着糖基化的多肽。